Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03701399Phase 3Active, not recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in spinocerebellar ataxia (SCA) comparing Troriluzole with Placebo (2 arms). Primary endpoint: Modified Functional Scale for the Assessment and Rating of Ataxia Total Score at 48 weeks. Started Mar 2019; status: active, not recruiting.
02
Drugs
troriluzole
03
Conditions
spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on NCT03701399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701399.